Egypt. J. Chem. Vol. 67, SI: M. R. Mahran, pp. **1361 - 1371** (2024)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

The Biochemistry of Immune Checkpoint Inhibitors and The Role of Nursing in Cancer Care.

Ohud Yousef Fahad Almutlaq[1], Rasheed Dohaim Abdulah Aldosari[1], Munira Masmar Misfer Al-Qahtani[1], Refah Ibrahim Fahad Aldawsari[2], Hanan Ahmed Alhomain[3], Norah Saed Ali Alamri[4], Shamsah Saeed Ali Alammri[5], Abdulaziz Khalid Alzaagi[6], Wafaa Mohammed Alhamed[7], Malikah Mohammed Hathal Alanazi[8], Amnah Mohamad Hadi[9], Mohammad Hossan Al Hoaidy[5], Amani Mabkhoot Mohammed AlSaiari[10], Fatma Ali Al Anzezi[11], Fatimah Mosa Kriry[12]

1 First Health Cluster, Ministry of Health, Saudi Arabia
2 Al-Yamamah Health Center in Al-Kharj, the first health cluster, Ministry of Health, Saudi Arabia
3 Al-Kharj, the first health cluster, Ministry of Health, Saudi Arabia
4 King Khalid Hospital, Ministry of Health, Saudi Arabia
5 Riyadh First Health Cluster, Ministry of Health, Saudi Arabia
6 King Salman Hospital, the First Health Cluster in Riyadh, Ministry of Health, Saudi Arabia
7 Aljazerah primary health care center, Ministry of Health, Saudi Arabia
8 Dhahrat Al Badia Health Care Center, Ministry of Health, Saudi Arabia
9 Al-Jouf Gathering, Ministry of Health, Saudi Arabia.
10 Al Eman general hospital, Ministry of Health, Saudi Arabia
11 Second health Cluster, Ministry of Health, Saudi Arabia
12 Nursing, Ministry of Health, Saudi Arabia

Abstract

Introduction: Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has become a groundbreaking approach in cancer treatment. This includes therapies targeting the PD-1/PD-L1 and CTLA-4 pathways to enhance the immune system's ability to recognize and attack cancer cells. Several cancers, including melanoma, lung, kidney, and colorectal cancer, are treated using ICIs. However, despite their efficacy, ICIs are associated with immune-related adverse events (irAEs) that can range from mild to life-threatening, affecting various body systems such as the skin, gastrointestinal tract, liver, and endocrine organs.

Aim: This article explores the biochemistry of immune checkpoint inhibitors, their mechanisms of action, the impact of irAEs, and the crucial role of nursing in managing these adverse events. It emphasizes the need for nurses to monitor, educate, and intervene to mitigate the risks associated with ICIs, ensuring better patient outcomes during cancer treatment.

Methods: A comprehensive review of current literature, clinical guidelines, and case studies on the mechanisms, types, and management of irAEs related to ICIs was conducted. The review also covers the nursing interventions necessary for the early detection, management, and education of patients receiving immunotherapy.

Results: Immune checkpoint inhibitors work by disrupting the immune system's negative regulation, restoring the body's immune response against tumors. However, irAEs occur as a result of this enhanced immune response, leading to systemic inflammation that can damage healthy organs. Nurses play a critical role in identifying early signs of irAEs, educating patients on symptoms, and coordinating care to minimize these effects. Nursing protocols include monitoring patients for signs of toxicity, providing symptom management, and educating patients on reporting adverse symptoms, even those occurring long after treatment cessation.

Conclusion: While ICIs have revolutionized cancer treatment, their associated irAEs require vigilant monitoring and management. Nurses are at the forefront of ensuring safe and effective cancer care through early detection, prompt intervention, and continuous patient education. Integrating these practices into routine clinical care can improve patient outcomes, reducing the severity of irAEs and enhancing the therapeutic benefits of ICIs.

Key words: Immune checkpoint inhibitors, cancer treatment, immune-related adverse events, nursing care, patient education, immunotherapy, toxicity management, cancer nursing, PD-1, CTLA-4.

1. Introduction

Immunotherapy, in particular immune checkpoint inhibitors (ICIs), has become a vital component of cancer treatment in recent years, supplementing more conventional treatments including radiation, chemotherapy, surgery, and targeted therapies (1). Prominent ICIs include programmed death-1 receptor (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA4). Lung cancer, melanoma, kidney cancer, head-and-neck cancer, colorectal cancer, and other cancers have all been

*Corresponding author e-mail: oyalmutlaq@moh.gov.sa.; (Ohud Yousef Fahad Almutlaq).
Receive Date: 13 November 2024, Revise Date: 25 November 2024, Accept Date: 01 December 2024
DOI: 10.21608/ejchem.2024.336211.10794

approved by the FDA for these treatments (2). However, there are also notable immune-related adverse events (irAEs) linked to ICI use (3). Leading oncology organizations, including the American Society of Clinical Oncology (3), European Society of Medical Oncology (3,5), Society for Immunotherapy of Cancer (4), and National Comprehensive Cancer Network (6), as well as nursing organizations, such as the Oncology Nursing Society (7) and Melanoma Nursing Initiative (8), have created guidelines that outline diagnosis, grading, treatment, and hospital care protocols in order to improve the management of irAEs. However, there is still a dearth of thorough studies on follow-up treatment. ICI-induced immune-related adverse effects can impact almost every body system (3). The skin, colon, liver, lungs, and endocrine organs are affected by the most frequent irAEs. Monotherapy with a single-agent ICI can result in up to 90% of any-grade adverse events (9,10). Of them, 20% to 43% of patients experience ≥Grade 3 irAEs (11), which have a 2% mortality rate (12). Combining ICIs, particularly with a CTLA-4 inhibitor, significantly increases the risk of irAEs. Colitis, hypophysitis, and rashes are the most prevalent adverse drug events (irAEs) associated with CTLA-4 monotherapy, while vitiligo, pneumonia, hypothyroidism, and arthralgia are more frequently associated with anti-PD-1 medication (13). Although the data is still up for debate, research on the relationship between irAEs and clinical outcomes, including progression-free survival and overall survival, is still ongoing (14,15,16,17,18).



Figure 1: Checkpoint Inhibitors.

Characteristics and Mechanisms of Immune-Related Adverse Events:

By attaching to particular immune checkpoints, immune checkpoint inhibitors (ICIs) eliminate immunosuppressive effects and restore T cell function and proliferation, strengthening the body's immunological response against cancer. However, immunological checkpoints are essential for immune homeostasis, and ICIs can disturb immune tolerance and harm healthy tissues or organs by blocking them (3). The nature and processes of adverse events (irAEs) are different from those caused by chemotherapy, targeted therapy, or other traditional cancer treatments. Therefore, giving patients receiving such medications the best care possible requires a full grasp of irAE features. With symptoms including fatigue, diarrhea, and rash that are frequently nonspecific and could be confused for symptoms of other ailments, adverse events (irAEs) can have serious repercussions, such as neurological problems and myocarditis. Furthermore, they can exhibit laboratory or imaging abnormalities that resemble the course of cancer or adverse effects of chemotherapy, which makes it simple for patients and healthcare professionals to ignore them (19). Additionally, compared to chemotherapy-related adverse events, immunotherapy-related adverse events (irAEs) usually appear weeks to three months after the start of immunotherapy, but they can also appear months or even years after the medication is stopped (20).

Treatment Principles:

The Common Terminology Criteria for Adverse Events (CTCAE), which goes from 1 (mild) to 4 (life-threatening), is the standard for rating

adverse events (irAEs), according to guidelines from several organizations (3,4,5,6). The majority of irAEs are categorized as either Grade 2 (moderate, with moderate symptoms disrupting daily activities) or Grade 1 (mild, asymptomatic, or slightly symptomatic). Regular monitoring is crucial for Grade 1 irAEs, and depending on the organs affected and the symptoms, conservative ICI therapy may continue. ICIs are often stopped for Grade 2 irAEs, and oral corticosteroids are recommended instead. ICIs are typically completely stopped and high-dose corticosteroids are given in cases of Grade 3 (severely symptomatic, considerably disrupting daily living) or Grade 4 (life-threatening) adverse events. Although mycophenolate is frequently favored due to its liver toxicity, infliximab may be tried if a response is not seen after 72 hours of high-dose corticosteroids. It is generally not recommended to restart ICI therapy until the adverse events reduce to Grade 1, particularly for Grade 4 or fatal irAEs.

Follow-up Care for Immune-Related Adverse Events:

Since early detection and intervention are essential to reducing the severity of irAEs, healthcare providers must continue to be on the lookout for their onset. An irAE should be explored if toxic sequelae from previous therapies worsen. Prior to starting immunotherapy, baseline symptom evaluation, laboratory testing, physical examination, and imaging are utilized as reference points to detect any clinical, biological, or imaging abnormalities after treatment, as specified in pertinent guidelines (3,4,5,6). At the start of treatment, throughout the course of the therapy, and even after it is stopped, close observation is required. It is advised that this surveillance be carried out for a maximum of 12 months after immunotherapy stops.

Contents and Timing of Immune-Related Adverse Events (irAEs)

Symptom Assessment and Patient Education:

Nurses and patients must be educated about the full range of immune-related adverse events (irAEs) and their potential timelines. It is crucial for patients to promptly report any unusual symptoms, even those that appear months after immunotherapy discontinuation. Carrying an immunotherapy wallet card is essential, as it informs emergency departments and other healthcare providers about the patient's immunotherapy regimen and associated irAEs.

1. **Dermatologic IrAEs:** Dermatologic irAEs occur in 30%-50% of patients, usually within the first two cycles of immune checkpoint inhibitor (ICI) therapy. Symptoms include pruritus, erythematous rash, alopecia, vitiligo, and bullous dermatitis. Rare but serious complications such as Stevens–Johnson syndrome or toxic epidermal necrolysis may occur and require immediate inpatient care, with consultations from multiple specialties.
2. **Gastrointestinal IrAEs:** Gastrointestinal irAEs, including diarrhea and colitis, affect 27%-54% of patients on CTLA-4 therapy. These symptoms typically arise within 5-8 weeks after treatment initiation but may recur even after therapy is stopped. Common symptoms include abdominal pain, bloating, diarrhea, and bloody stools.
3. **Hepatic Toxicity:** Hepatotoxicity occurs in 3%-9% of CTLA-4 and 1%-2% of PD-1/PD-L1 therapies, typically around 6-14 weeks post-treatment initiation. Symptoms include jaundice, abdominal pain, ascites, and mental status changes.
4. **Endocrine Toxicity:** Endocrine irAEs, including hypophysitis, thyroid dysfunction, and adrenal insufficiency, occur in 20% of patients. Symptoms may include nausea, weight loss, fatigue, and cognitive dysfunction. Treatment involves hormone replacement therapy. Rare but potentially fatal conditions include adrenal insufficiency and diabetic ketoacidosis.
5. **Pneumonitis:** Pneumonitis, occurring in 3%-5% of ICI patients, is more common with PD-1/PD-L1 inhibitors, especially in patients with lung or renal cancer. Symptoms include dyspnea, dry cough, and severe respiratory failure. Around one-third of cases are asymptomatic and only diagnosed through routine imaging.
6. **Cardiac Toxicity:** Although rare (1%), cardiac irAEs have a high mortality rate (23%). Symptoms may include fatigue, chest pain, heart failure, and arrhythmia, requiring rapid diagnosis and treatment.
7. **Renal Toxicity:** Renal irAEs, such as nephritis, lead to acute kidney insufficiency and are usually asymptomatic, though some patients may present with oliguria, hematuria, and peripheral edema.
8. **Musculoskeletal and Rheumatologic IrAEs:** Musculoskeletal irAEs, including arthralgia and myalgia, occur in 1%-43% of patients, typically between 2-17 weeks after ICI therapy. These symptoms may be overlooked, as they resemble common joint and muscle issues.
2. **Neurological IrAEs:** Neurological irAEs include myasthenia gravis, Guillain–Barre

syndrome, and peripheral neuropathy. Symptoms may include altered mental status, headaches, and seizures.

3. **Eye Toxicity:** Common eye toxicities, such as uveitis and optic edema, often present as blurred vision, photophobia, and altered visual fields. Patients should be monitored for these symptoms, as they may require specialized care.
4. **Nurse's Role in Monitoring irAEs:** Nurses need to be aware of the symptoms associated with irAEs, especially those related to cardiac, neurological, and respiratory complications, which require immediate evaluation and treatment. Additionally, patients should be educated to recognize common irAEs and report any discomfort promptly. This proactive approach can help mitigate the severity and duration of irAEs (21-51).

Laboratory Tests

Since many immune-related adverse events (irAEs) may present as laboratory anomalies rather than clinical symptoms, laboratory examinations form the basis for continuing care reviews (3,4,5,6). The following should be included in the list of necessary baseline laboratory tests: (1) general blood tests, such as a complete blood count (CBC) with differential, a comprehensive metabolic panel (CMP), fasting lipid profile, glycosylated hemoglobin, and glycated hemoglobin; (2) screening for infectious diseases, such as hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, hepatitis C antibody, cytomegalovirus antibody, T-spot test (TB), HIV antibody, and HIV antigen (p24); (3) serum creatinine and cardiac markers, such as total creatinine kinase, troponin 1, brain natriuretic peptide, and N-terminal pro B-type natriuretic peptide; (4) endocrine evaluations, such as thyroid-stimulating hormone, free thyroxine (T4), total triiodothyronine (T3), morning cortisol, and morning adrenocorticotropic hormone (ACTH). In order to detect adverse events (irAEs) early through laboratory data before clinical signs appear, routine monitoring during therapy should include the following: CBC differential and CMP prior to each infusion; thyroid function tests every 6–8 weeks; ACTH and morning cortisol at regular intervals during and after treatment; and additional blood tests as clinically indicated (6).

Physical Examination

At baseline and before each infusion or possible adverse event, a comprehensive physical assessment is necessary (3,4,5,6). A thorough assessment of the skin and mucous membranes (noting the extent and kind of lesions), baseline oxygen saturation in room air and during ambulation, pulmonary function tests, and a 6-minute walk test, an electrocardiogram (ECG), joint examination and functional assessment, and a neurologic and brain assessment are all important components of the examination.

Imaging

Baseline imaging with computed tomography (CT) or brain magnetic resonance imaging (MRI) is essential. Periodic CT scans during treatment are recommended to monitor for pneumonitis, and MRI should be used if symptoms such as headaches arise or if hypophysitis is suspected (3,4,5,6).

Side Effect Management

Corticosteroids and other immunomodulatory treatments are the mainstays of managing irAEs. Initial corticosteroid doses for Grade 3/Grade 4 irAEs usually range from 1 mg/kg to 2 mg/kg, or prednisone may be added, and treatment lasts for at least 4–6 weeks (52). Multiple body systems may experience long-term complications, such as musculoskeletal problems (osteoporosis, osteonecrosis, steroid myopathy), digestive problems (peptic ulcers, bleeding, pancreatitis, fatty liver), cardiovascular problems (hypertension, arteriosclerosis, arrhythmias), metabolic disorders (glucose and lipid metabolism irregularities, water and sodium imbalances, electrolyte disruptions, adrenal axis inhibition, gonadal suppression, increased appetite, weight gain), mental health effects (insomnia, emotional instability, cognitive impairment), opportunistic infections (fungal, tuberculosis), and dermatological problems (cataracts, glaucoma, acne, striae, fragile skin, ecchymosis, hirsutism, non-healing wounds) (5). In order to identify infections, it is essential to monitor blood pressure, glucose, electrolytes, and output while taking medicine. Proton pump inhibitors or H2 receptor antagonists can be used in conjunction with high dosages of corticosteroids to prevent stomach damage. Instructing patients to take corticosteroids with food, stay away from infectious sources, control their diet to avoid gaining too much weight, and keep an eye on their blood sugar levels are all important. To prevent rebound effects, corticosteroids should be reduced

gradually (over a minimum of one month) after symptoms are under control (5).

Models and Effects

Traditional models typically involve face-to-face visits in clinical or home settings or follow-ups via mail, phone, telemedicine, or web-based portals. Given the intensive and prolonged follow-up required for patients undergoing immune checkpoint inhibitor (ICI) treatment, a more efficient, labor- and time-saving follow-up model is necessary. However, relevant research, particularly within nursing, remains limited.

Telephone Triage

Telephone follow-up is a common method of continuing nursing care, though it presents more challenges compared to in-person visits, especially due to the variable manifestations of irAEs. Hoffner et al. (54) highlighted the importance of improving telephone triage systems and incorporating dedicated oncology acute care services to alleviate the burden of irAE management. The Immuno-Oncology Essentials guidelines developed by the Melanoma Nursing Initiative (7) provide a framework for triaging irAEs over the phone. Patients and caregivers should be educated to recognize and report early signs of irAEs, enhancing the effectiveness of telephone triage.

Multidisciplinary Collaboration

From October 2019 to February 2020, Le et al. (55) evaluated the effects of a pharmacist-led strategy for controlling irAEs in 17 patients at the University of Wisconsin Carbone Cancer Center. In-person training and instructional materials that summarized current procedures and ICIs were provided to emergency department (ED) nurses. They directed patients to oncology pharmacists after identifying possible irAEs. Based on guidelines, the pharmacists suggested therapies and verified the existence of irAEs. During inpatient stays, they also conducted daily follow-ups to track treatment outcomes and any new adverse events. 33 recommendations were provided, and nine of the 17 patients were treated in accordance with the pharmacist's regimen until the toxicity was resolved. This method improved physician confidence in managing irAEs and decreased their burden.

Electronic Patient Report Outcomes (ePRO)

The ePRO model is a new follow-up strategy that makes fast, continuous, and cost-effective data collecting possible. Patients fill out health-related questionnaires to describe symptoms and the severity of irAEs (56,57). According to studies, ePROs can improve performance status, lower emergency visits, improve quality of life (QoL), and minimize the proportion of patients who need aggressive cancer treatments as their disease progresses (58). Using ePROs to manage cancer patients led to greater quality of life, fewer ER visits, fewer hospitalizations, longer duration of palliative treatment, and increased quality-adjusted survival, according to Basch et al. (59). Iivanainen et al. (60) examined the viability of ePROs in 37 adult cancer patients receiving anti-PD-L1 drugs, despite the fact that few research have concentrated on ePRO follow-up for cancer patients on ICIs. Typical side effects were evaluated by weekly questionnaires, and an algorithm was used to determine the severity of the symptoms and notify the care team. By recording a wide range of symptoms associated with treatment results, the study proved that ePRO follow-ups are feasible and could result in prediction models for specific patients. An eHealth intervention was used by Tolstrup et al. (52) for 57 patients with malignant melanoma receiving treatment. High patient and clinician satisfaction was demonstrated by weekly tablet-based symptom reporting and mixed-methods evaluation, suggesting that eHealth tools improve patient involvement and symptom awareness. Wang et al. (61) treated 72 patients with intestinal cancer with immunotherapy and ongoing follow-up care. Nurses provided one-on-one instruction, frequent lectures, and home and phone follow-up. The experimental group outperformed the control group in terms of satisfaction and quality of life, according to the results. Zhang et al. (62) examined 536 immunotherapy patients and compared follow-up using a web-based approach with manual follow-up. The usefulness of web-based follow-up systems in enhancing patient outcomes was demonstrated by the experimental group's increased satisfaction, treatment compliance, and decreased follow-up loss.

Suggestions and Barriers

Based on patient volume and available medical resources, healthcare professionals must select appropriate follow-up strategies. Collaboration between hospitals and community health resources can be used in more developed areas. Electronic follow-up platforms like smartphones, email, or services like Tencent QQ could be used for younger patients who are adept with digital gadgets. Online medical visits may be advantageous in regions with well-established e-health systems. Home visits or phone follow-ups are feasible options for medical facilities with fewer patients or enough follow-up personnel. On the other hand, in some situations, techniques like ePRO that require less work might be

better. Nonetheless, immunotherapy patients' current follow-up is still insufficient. Effective follow-up is hampered by a number of factors. First, because immunotherapy is a relatively new treatment, nurses may not have the necessary training, expertise, or awareness to properly follow up with these patients. Second, the high daily workloads caused by a nursing staff shortage make standard follow-up techniques, such phone calls, too taxing. Third, there is a financial barrier to implementation because electronic follow-up solutions like ePRO demand a large upfront expenditure.

Nursing Role in Cancer Treatment and Checkpoint Inhibitors:

The role of nursing professionals in cancer treatment has evolved significantly in recent years, particularly with the advent of immunotherapies such as checkpoint inhibitors. Nurses are integral to the management of patients undergoing cancer treatment, as they are directly involved in the administration, monitoring, education, and support of patients. Checkpoint inhibitors, a class of immunotherapy drugs that have revolutionized cancer care, work by enhancing the body's immune system to recognize and attack cancer cells. These therapies have become essential in treating various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. This article explores the critical role of nurses in cancer treatment, focusing on their responsibilities and interventions when caring for patients receiving checkpoint inhibitors.

Understanding Checkpoint Inhibitors in Cancer Treatment

Checkpoint inhibitors are a type of immunotherapy that blocks checkpoint proteins from inhibiting the immune response. These proteins, such as PD-1, PD-L1, and CTLA-4, normally function to keep the immune system from attacking healthy cells. However, cancer cells can exploit these proteins to avoid detection by the immune system. By inhibiting these checkpoint proteins, checkpoint inhibitors can restore immune function, allowing the body’s natural defenses to target and destroy cancer cells. While these therapies have shown remarkable efficacy in certain cancers, they also present unique challenges, including immune-related adverse events (irAEs), which can affect multiple organ systems.

The Role of Nurses in Cancer Care

Nurses are crucial in cancer care, providing direct patient care and offering a range of supportive services. Their role encompasses the physical, psychological, and emotional support needed by patients, ensuring that cancer treatments, including immunotherapies like checkpoint inhibitors, are administered safely and effectively. In the context of immunotherapy, nurses are responsible for the education and monitoring of patients, recognizing adverse events early, managing symptoms, and coordinating interdisciplinary care.

Patient Education and Informed Consent

One of the primary responsibilities of nurses in the management of cancer patients receiving checkpoint inhibitors is educating patients about the treatment process. Nurses must ensure that patients are fully informed about the potential benefits and risks of checkpoint inhibitors. This includes explaining how the treatment works, what side effects they may experience, and the importance of adhering to the treatment regimen. Additionally, nurses play a critical role in obtaining informed consent, ensuring that patients understand the potential adverse effects of treatment, particularly immune-related adverse events (irAEs), which can range from mild to severe. Given the relatively new nature of immunotherapies such as checkpoint inhibitors, many patients may have limited understanding of these treatments. Nurses, therefore, need to provide clear and concise information and address any concerns or misconceptions that patients and their families may have. This education also extends to post-treatment care, where patients must be advised on what symptoms to monitor for and when to seek medical attention.

Monitoring and Early Detection of Immune-Related Adverse Events

One of the most critical aspects of nursing care for patients on checkpoint inhibitors is the early detection and management of irAEs. Since checkpoint inhibitors can cause the immune system to attack healthy tissues, patients may experience side effects that involve various organs, including the skin, lungs, gastrointestinal system, liver, and endocrine glands. These adverse events can be life-threatening if not recognized and managed promptly. Nurses are responsible for monitoring patients throughout their treatment journey. This includes regular assessments of vital signs, laboratory tests, and physical examinations. Early detection of irAEs is essential for preventing severe complications. Nurses must be trained to recognize symptoms such as rashes, fever, fatigue, gastrointestinal distress, and respiratory difficulties, all of which may signal an irAE. Additionally, nurses are tasked with ensuring that

patients undergo appropriate baseline and follow-up laboratory tests, such as liver function tests and thyroid function tests, to identify any irregularities that might indicate an adverse reaction to treatment. In many cases, irAEs can be managed effectively if identified early, often with corticosteroids or other immunosuppressive treatments. Nurses must be familiar with the management protocols for these side effects, ensuring timely intervention and coordination with the healthcare team.

Administration and Management of Treatment

Nurses are directly involved in the administration of checkpoint inhibitors, often administering these therapies through intravenous infusion. Proper preparation and understanding of the drug's pharmacodynamics are crucial to ensuring patient safety. Nurses must follow specific protocols for the preparation, dosage, and administration of these treatments to avoid errors and minimize the risk of adverse reactions. Moreover, nursing staff are responsible for closely monitoring patients during and after the infusion. Infusion-related reactions, although uncommon, can occur and may include symptoms such as chills, fever, nausea, and difficulty breathing. Nurses must be prepared to manage these reactions promptly, ensuring the patient's safety and comfort. Post-infusion care is also an important aspect of nursing responsibility. Following the administration of checkpoint inhibitors, patients may experience delayed side effects. Nurses must provide thorough post-care instructions and ensure that patients are aware of the potential signs and symptoms of adverse reactions that may develop in the days or weeks following treatment. This follow-up care is essential in preventing complications and ensuring that patients remain safe while receiving immunotherapy.

Psychosocial Support and Patient Advocacy

The emotional and psychological toll of cancer treatment can be overwhelming for many patients. Nurses play a vital role in providing psychosocial support, addressing the emotional and mental health needs of patients. This includes offering counseling, providing resources for support groups, and helping patients cope with the anxiety, fear, and uncertainty that often accompany cancer treatment. In addition to providing direct psychosocial support, nurses act as advocates for their patients. They work to ensure that patients' needs are met throughout their treatment journey, advocating for timely access to services, appropriate symptom management, and a patient-centered care approach. In the context of immunotherapy, nurses may also assist in ensuring that patients have access to necessary follow-up care, such as regular monitoring and consultations with oncologists, to ensure the success of their treatment regimen.

Multidisciplinary Collaboration

Effective cancer care often requires collaboration among multiple healthcare professionals. Nurses are key members of the multidisciplinary team, working alongside oncologists, pharmacists, nutritionists, social workers, and other specialists to provide comprehensive care. This collaborative approach is especially critical in managing patients receiving checkpoint inhibitors, as the complexities of immunotherapy often require input from various experts. Nurses communicate patient concerns, treatment responses, and potential side effects to the team, facilitating timely interventions and adjustments to the treatment plan. For example, if a patient experiences a significant irAE, the nurse can alert the oncology team, ensuring that the appropriate steps are taken, whether that involves adjusting the treatment regimen or initiating symptom management protocols.

Challenges in Nursing Care for Checkpoint Inhibitor Treatment

While the role of nurses in managing patients receiving checkpoint inhibitors is crucial, several challenges remain. The rapid pace of advancements in cancer treatment, including immunotherapies, means that nurses must continually update their knowledge and skills to keep pace with new therapies and protocols. This requires ongoing professional development and training, particularly in recognizing and managing irAEs, which are often unpredictable and vary widely in severity. Another challenge is the potential for a high workload, especially in healthcare systems with limited resources. Nurses are often tasked with managing multiple patients simultaneously, which can lead to burnout and stress. Inadequate staffing, combined with the growing complexity of cancer treatments, increases the demands placed on nurses, potentially affecting the quality of care provided. The role of nurses in the administration and management of cancer patients receiving checkpoint inhibitors is multifaceted and essential to the success of the treatment regimen. Nurses are responsible for educating patients, monitoring adverse effects, administering treatments, providing emotional support, and advocating for patient needs. Given the unique nature of immunotherapy and the potential for severe immune-related adverse events, the role of nurses becomes

even more critical. By continuing to build expertise in this area, nurses can ensure that patients undergoing checkpoint inhibitor therapy receive the safest and most effective care possible, contributing significantly to improved outcomes in cancer treatment.

Conclusion:

Immune checkpoint inhibitors (ICIs) represent a significant advancement in cancer therapy, providing promising results in the treatment of several cancers. However, the emergence of immune-related adverse events (irAEs) complicates the use of these therapies and poses a challenge for healthcare providers. ICIs, by enhancing the immune system's ability to combat cancer, inadvertently disrupt immune tolerance, leading to potential damage in healthy tissues and organs. The nature of irAEs—ranging from mild to severe and affecting multiple organ systems—demands close monitoring, early intervention, and specialized care. Nurses play a pivotal role in the management of patients undergoing immunotherapy. Their responsibilities extend beyond the administration of the drug to include early recognition of irAEs, patient education, and providing ongoing support. The identification and timely management of irAEs are crucial in preventing long-term complications and improving patient outcomes. Nurses must be proficient in recognizing the diverse symptoms of irAEs, ranging from dermatologic reactions to gastrointestinal, hepatic, and endocrine disorders. In some cases, these adverse events can mimic the symptoms of the underlying disease or other therapies, making early detection and differential diagnosis essential. In addition to recognizing symptoms, nurses are instrumental in educating patients about the potential risks associated with ICIs. This includes informing patients about the possible onset of irAEs weeks or even months after treatment initiation, as well as the importance of reporting new or unusual symptoms promptly. Patient education on carrying an immunotherapy wallet card that details their treatment regimen and possible irAEs is also vital in managing emergencies, particularly during hospital visits or in cases of delayed symptoms. Effective management of irAEs requires a multidisciplinary approach, where nurses collaborate with oncologists, pharmacists, and other healthcare professionals to adjust treatments as needed, administer supportive care, and prevent complications. Nurses are also responsible for the ongoing monitoring of patients' laboratory values, physical examinations, and imaging studies to detect irAEs before they reach critical levels. This proactive care approach significantly reduces the risks of severe outcomes associated with immune-related toxicities. In conclusion, the role of nursing in cancer care, particularly in managing patients receiving ICIs, is indispensable. Nurses provide critical support through early identification, education, and intervention, ensuring that patients can continue their cancer treatment safely while minimizing the impact of irAEs. The integration of nursing knowledge and expertise in immunotherapy management not only enhances patient care but also contributes to the overall success of cancer treatments with immune checkpoint inhibitors.

References:

1. Smyth, M. J., & Teng, M. W. (2018). The 2018 Nobel Prize in physiology or medicine. Clinical and Translational Immunology, 7(1), e1041. https://doi.org/10.1002/cti2.1041
2. Seidel, J. A., Otsuka, A., & Kabashima, K. (2018). Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations. Frontiers in Oncology, 8, 86. https://doi.org/10.3389/fonc.2018.00086
3. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology, 36(17), 1714–1768. https://doi.org/10.1200/JCO.2018.78.1022
4. Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O. 3rd, Brogdon, C., Dadu, R., et al. (2017). Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. Journal for ImmunoTherapy of Cancer, 5(1), 95. https://doi.org/10.1186/s40425-017-0316-z
5. Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., et al. (2017). Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology, 28(iv119–iv142). https://doi.org/10.1093/annonc/mdx225
6. Thompson, J. A. (2017). New NCCN guidelines: Recognition and management of immunotherapy-related toxicity. Journal of the National Comprehensive Cancer Network, 15(5), 594–596. https://doi.org/10.6004/jnccn.2017.0055
7. Rubin, K. M. (2015). Managing immune-related adverse events to ipilimumab: A nurse's guide.

Clinical Journal of Oncology Nursing, 19(1), E69–E75. https://doi.org/10.1188/15.CJON.E69-E75

8. McGettigan, S., & Rubin, K. M. (2017). PD-1 inhibitor therapy: Consensus statement from the faculty of the melanoma nursing initiative on managing adverse events. Clinical Journal of Oncology Nursing, 21(1), 42–51. https://doi.org/10.1188/17.CJON.42-51
9. Eggermont, A. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., et al. (2016). Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. New England Journal of Medicine, 375(19), 1845–1855. https://doi.org/10.1056/NEJMoa1603553
10. Kennedy, L. B., & Salama, A. K. (2020). A review of cancer immunotherapy toxicity. CA: A Cancer Journal for Clinicians, 70(2), 86–104. https://doi.org/10.3322/caac.21557
11. Kumar, V. (2017). Current diagnosis and management of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in Pharmacology, 8, 49. https://doi.org/10.3389/fphar.2017.00049
12. Pennock, G. K., & Chow, L. Q. (2018). The evolving role of immune checkpoint inhibitors in cancer treatment. The Oncologist, 23(7), 812–822. https://doi.org/10.1634/theoncologist.2017-0455
13. Khoja, L., Day, D., Wei-Wu, C., Siu, L. L., & Hansen, A. R. (2017). Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review. Annals of Oncology, 28(11), 2377–2385. https://doi.org/10.1093/annonc/mdx344
14. Rogado, J., Sánchez-Torres, J. M., Romero-Laorden, N., Ballesteros, A. I., Pacheco-Barcia, V., Ramos-Leví, A., et al. (2019). Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. European Journal of Cancer, 112, 21–27. https://doi.org/10.1016/j.ejca.2019.01.010
15. Elias, R., Yan, N., Singla, N., Perrone, F., Minari, R., Bersanelli, M., et al. (2020). Immune related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients. Journal of Clinical Oncology, 38(15), 645A. https://doi.org/10.1200/JCO.2020.38.15_suppl.645A
16. Grangeon, M., Tomasini, P., Chaleat, S., Jeanson, A., Souquet-Bressand, M., Khobta, N., et al. (2019). Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clinical Lung Cancer, 20(3), 201–207. https://doi.org/10.1016/j.cllc.2018.07.004
17. Greally, M., Chou, J. F., Chatila, W. K., Margolis, M., Capanu, M., Hechtman, J. F., et al. (2018). Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. Clinical Cancer Research, 24(16), 6160–6169. https://doi.org/10.1158/1078-0432.CCR-17-2393
18. Okada, N., Kawazoe, H., Takechi, K., Matsudate, Y., Utsunomiya, R., Zamami, Y., et al. (2019). Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: A multicenter retrospective study. Clinical Therapeutics, 41(1), 59–67. https://doi.org/10.1016/j.clinthera.2018.10.005
19. Daly, B., Nicholas, K., Gorenshteyn, D., Sokolowski, S., Gazit, L., Adams, L., et al. (2018). Misery loves company: Resentment of symptom clusters to urgent care by patients receiving antineoplastic therapy. Journal of Oncology Practice, 14(6), e492–e495. https://doi.org/10.1200/JOP.18.00399
20. Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481
21. Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., et al. (2016). Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Annals of Oncology, 27(5), 559–574. https://doi.org/10.1093/annonc/mdw123
22. Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., et al. (2016). Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor. European Journal of Cancer, 52, 12–25. https://doi.org/10.1016/j.ejca.2015.09.004
23. Sibaud, V. (2019). Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. American Journal of Clinical Dermatology, 20(3), 345–361. https://doi.org/10.1007/s40257-019-00424-1
24. Gupta, A., Defelice, K. M., Lofeus, E. V., & Khanna, S. (2017). Systematic review: Colitis with immune checkpoint inhibitors. Current Opinion in Gastroenterology, 33(6), 453–459. https://doi.org/10.1097/MOG.0000000000000397
25. Magro, C. M., & Crowson, A. N. (2017). Immune-related adverse events: Pathology, pathogenesis, and management. Journal of

Clinical Pathology, 70(8), 694–704. https://doi.org/10.1136/jclinpath-2017-203816
26. Abdel-Rahman, O., ElHalawani, H., & Fouad, M. (n.d.). Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Immunotherapy, 1213–1227.
27. De Martin, E., Michot, J. M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., et al. (n.d.). Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. Journal of Hepatology, 1181–1190.
28. Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., et al. (n.d.). Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncology, 173–182.
29. Caturegli, P., Di Dalmazi, G., Lombardi, M., Grosso, F., Larman, H. B., Larman, T., et al. (n.d.). Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series. American Journal of Pathology, 3225–3235.
30. Chang, L. S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (n.d.). Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocrine Reviews, 17–65.
31. de Filette, J., Andreescu, C. E., Cools, F., Bravenboer, B., & Velkeniers, B. (n.d.). A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Hormone and Metabolic Research, 145–156.
32. Faje, A. T., Sullivan, R., Lawrence, D., Tritos, N. A., Fadden, R., Klibanski, A., et al. (n.d.). Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Journal of Clinical Endocrinology & Metabolism, 4078–4085.
33. Ariyasu, H., Inaba, H., Ota, T., Yamaoka, H., Furukawa, Y., Iwakura, H., et al. (n.d.). Thyrotoxicosis and adrenocortical hormone deficiency during immune checkpoint inhibitor treatment for malignant melanoma. In Vivo, 345–351.
34. Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., et al. (n.d.). Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care, e55–e57.
35. Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., et al. (n.d.). Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes, 1471–1480.
36. Hu, Y. B., Zhang, Q., Li, H. J., Michot, J. M., Liu, H. B., Zhan, P., et al. (n.d.). Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A meta-analysis. Translational Lung Cancer Research, S8–S20.
37. Suresh, K., Voong, K. R., Shankar, B., Forde, P. M., Ettinger, D. S., Marrone, K. A., et al. (n.d.). Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: Incidence and risk factors. Journal of Thoracic Oncology, 1930–1939.
38. Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (n.d.). The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: A meta-analysis. Frontiers in Pharmacology, 1430.
39. Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., et al. (n.d.). Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncology, 895–903.
40. Voong, K. R., Hazell, S. Z., Fu, W., Hu, C., Lin, C. T., Ding, K., et al. (n.d.). Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clinical Lung Cancer, e470–e479.
41. Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., et al. (n.d.). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Ocology, 709–717.
42. Khunger, M., Rakshit, S., Pasupuleti, V., Hernandez, A. V., Mazzone, P., Stevenson, J., et al. (n.d.). Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials. Chest, 271–281.
43. Delaunay, M., Cadranel, J., Lusque, A., Nicolas Meyer, N., Gounant, V., Moro-Sibilot, D., et al. (n.d.). Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal, 170–185.
44. Grawal, N., Khunger, A., Vachhani, P., Colvin, T. A., Alexander Hattoum, A., Spangenthal, E., et al. (n.d.). Cardiac toxicity associated with immune checkpoint inhibitors: Case series and review of the literature. Case Reports in Oncology, 260–276.

45. Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., et al. (n.d.). Adverse renal effects of immune checkpoint inhibitors: A narrative review. American Journal of Nephrology, 160–169.
46. Cappelli, L. C., Gutierrez, A., Bingham, C. O., & Shah, A. A. (n.d.). Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. Arthritis Care & Research, 1751–1763.
47. Suarez-Almazor, M. E., Kim, S. T., Abdel-Wahab, N., & Diab, A. (n.d.). Review: Immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer. Arthritis & Rheumatology, 687–699.
48. Moseley, K. F., Naidoo, J., Bingham, C. O., Carducci, M. A., Forde, P. M., Gibney, G. T., et al. (n.d.). Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series. Journal of Immunotherapy Cancer, 104.
49. Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., et al. (n.d.). Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. European Journal of Cancer, 1–8.
50. Bricout, M., Petre, A., Amini-Adle, M., Bezza, W., Seve, P., Kodjikian, L., et al. (n.d.). Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. Journal of Immunotherapy, 77–82.
51. Matsuo, T., & Yamasaki, O. (n.d.). Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clinical Case Reports, 694–700.
52. Tolstrup, L. K., Pappot, H., Bastholt, L., Zwisler, A. D., & Dieperink, K. B. (2019). Patient-reported outcomes during immunotherapy for metastatic melanoma: Mixed methods study of patients' and clinicians' experiences. Journal of Medical Internet Research, 21(7), e14896. https://doi.org/10.2196/14896
53. Williams, K. J., Grauer, D. W., Henry, D. W., & Rockey, M. L. (2019). Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors. Journal of Oncology Pharmacy Practice, 25(3), 544-550. https://doi.org/10.1177/1078155219830943
54. Hoffner, B., & Rubin, K. M. (2020). Meeting the challenge of immune-related adverse events with optimized telephone triage and dedicated oncology acute care. Journal of the Advanced Practitioner in Oncology, 11(1), 9-20.
55. Le, S., Chang, B., Pham, A., & Chan, A. (2020). Impact of pharmacist-managed immune checkpoint inhibitor toxicities. Journal of Oncology Pharmacy Practice, 26(4), 596-600. https://doi.org/10.1177/1078155220904311
56. Holch, P., Warrington, L., Bamforth, L. C., Keding, A., Ziegler, L. E., Absolom, K., et al. (2020). Development of an integrated electronic platform for patient self-report and management of adverse events during cancer treatment. Annals of Oncology, 31(12), 2305-2311. https://doi.org/10.1016/j.annonc.2020.08.105
57. Jensen, R. E., Snyder, C. F., Abernethy, A. P., Basch, E., Potosky, A. L., Roberts, A. C., et al. (2019). Review of electronic patient-reported outcomes systems used in cancer clinical care. Journal of Oncology Practice, 15(3), e215-e222. https://doi.org/10.1200/JOP.18.00648
58. Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., et al. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(17), 197–198. https://doi.org/10.1001/jama.2017.11610
59. Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., et al. (2017). Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. Journal of Clinical Oncology, 35(18), 557-565. https://doi.org/10.1200/JCO.2016.69.798
60. Iivanainen, S., Alanko, T., Vihinen, P., Konkola, T., Ekstrom, J., Virtanen, H., et al. (2020). Follow-up of cancer patients receiving anti-PD-(L) 1 therapy using an electronic patient-reported outcomes tool (KISS): Prospective feasibility cohort study. JMIR Formative Research, 4(1), e16311. https://doi.org/10.2196/16311
61. Wang, P. (2019). Study on the application effect of continuous care in patients with digestive system tumor after immunization or targeted therapy. Family Medicine, 30(4), 334-335.
62. Zhang, S., Wang, Y., Wang, X. L., Hu, L. T., Xia, Q., Shi, C. C., et al. (2019). Application of follow-up system in patients with specific immunotherapy. China Digital Medicine, 4(2), 78-81.

.